Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Financials
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-09-29 am EDT
1905.00 JPY   +3.17%
06:49aLupin Gets US FDA Nod for Overactive Bladder Drug
MT
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/27US Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astellas' Lexiscan
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: March 2020 2021 2022 2023 2024 2025
Capitalization1 3 105 3953 161 4213 519 7383 428 504--
Enterprise Value (EV)1 2 777 5452 829 7333 203 7523 033 2912 890 8622 741 307
P/E ratio 16,0x26,2x28,5x16,5x13,8x12,0x
Yield 2,39%2,47%2,62%3,20%3,53%3,89%
Capitalization / Revenue 2,39x2,53x2,72x2,36x2,26x2,13x
EV / Revenue 2,14x2,26x2,47x2,09x1,90x1,70x
EV / EBITDA 8,95x13,6x13,6x8,34x7,27x6,16x
Price to Book 2,41x2,28x2,39x2,20x2,04x1,87x
Nbr of stocks (in thousands) 1 858 4051 857 4741 841 8311 827 074--
Reference price (JPY) 1 6711 7021 9111 8771 8771 877
Announcement Date 05/14/202004/27/202104/27/2022---
1 JPY in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: March 2020 2021 2022 2023 2024 2025
Net sales1 1 300 8431 249 5281 296 1631 454 3071 518 4101 611 265
EBITDA1 310 387208 703235 370363 841397 382444 762
Operating profit (EBIT)1 243 991136 051155 686262 941309 476356 011
Operating Margin 18,8%10,9%12,0%18,1%20,4%22,1%
Pre-Tax Profit (EBT)1 245 350145 324156 886261 098311 171357 927
Net income1 195 411120 589124 086205 892243 489279 824
Net margin 15,0%9,65%9,57%14,2%16,0%17,4%
EPS2 10464,967,1114136157
Dividend per Share2 40,042,050,060,066,373,0
Announcement Date 05/14/202004/27/202104/27/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3
Net sales1 340 627303 870381 791356 105748 000378 500
EBITDA ------
Operating profit (EBIT)1 79 202-13 68533 14779 527117 50090 150
Operating Margin 23,3%-4,50%8,68%22,3%15,7%23,8%
Pre-Tax Profit (EBT)1 78 317-10 51631 67995 700115 50084 900
Net income1 60 886-8 40924 81274 60090 00066 200
Net margin 17,9%-2,77%6,50%20,9%12,0%17,5%
EPS2 32,9-4,4313,635,246,639,4
Dividend per Share ------
Announcement Date 02/02/202204/27/202208/01/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: March 2020 2021 2022 2023 2024 2025
Net Debt1 ------
Net Cash position1 327 850331 688315 986395 213537 642687 197
Leverage (Debt / EBITDA) -1,06x-1,59x-1,34x-1,09x-1,35x-1,55x
Free Cash Flow1 -167 795275 459226 705213 290245 902270 824
ROE (Net Profit / Equities) 15,3%9,00%8,70%13,9%15,8%16,9%
Shareholders' equity1 1 277 1961 339 8781 426 2761 477 5011 544 5431 651 520
ROA (Net Profit / Asset) 11,6%6,33%6,81%8,85%9,68%10,4%
Assets1 1 678 8581 905 1211 821 5232 326 5132 515 9632 688 809
Book Value Per Share2 6947487998529201 005
Cash Flow per Share2 140104110147172192
Capex1 41 26731 38430 73950 48847 50848 508
Capex / Sales 3,17%2,51%2,37%3,47%3,13%3,01%
Announcement Date 05/14/202004/27/202104/27/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Key data
Capitalization (JPY) 3 428 504 270 928
Capitalization (USD) 23 738 172 616
Net sales (JPY) 1 296 163 000 000
Net sales (USD) 8 974 333 587
Number of employees 14 522
Sales / Employee (JPY) 89 255 130
Sales / Employee (USD) 617 982
Free-Float 98,9%
Free-Float capitalization (JPY) 3 390 755 751 357
Free-Float capitalization (USD) 23 476 810 575
Avg. Exchange 20 sessions (JPY) 9 605 457 675
Avg. Exchange 20 sessions (USD) 66 505 973
Average Daily Capital Traded 0,3%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA